دورية أكاديمية
أعرض في EDS

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

التفاصيل البيبلوغرافية
العنوان: Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis
المؤلفون: Mahtani RL, Parisi M, Glück S, Ni Q, Park S, Pelletier C, Faria C, Braiteh F
المصدر: Cancer Management and Research, Vol Volume 10, Pp 249-256 (2018)
بيانات النشر: Dove Medical Press, 2018.
سنة النشر: 2018
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Metastatic breast cancer, nab-paclitaxel, paclitaxel, hormone receptor positive, triple negative, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Reshma L Mahtani,1 Monika Parisi,2 Stefan Glück,3 Quanhong Ni,2 Siyeon Park,4 Corey Pelletier,2 Claudio Faria,2 Fadi Braiteh5,6 1Division of Hematology/Oncology, University of Miami, Miami, FL, 2Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ, 3Global Medical Affairs, Celgene Corporation, Summit, NJ, 4School of Pharmacy, The Ohio State University, Columbus, OH, 5Department of Hematology/Oncology, University of Nevada School of Medicine, Las Vegas, NV, 6Department of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA Background: Real-world analyses of treatments for patients with metastatic breast cancer are limited. We evaluated the comparative effectiveness of nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer using data from an electronic medical record database from community practices across the USA.Methods: We performed a retrospective cohort study using fully de-identified data from an independent US electronic medical record platform of patients with metastatic breast cancer initiating single-agent nab-paclitaxel or paclitaxel as a first- or second-line treatment from December 1, 2010 to October 6, 2014. The clinical efficacy objectives were time to treatment discontinuation (TTD) and time to next treatment (TTNT). Subgroup analyses were performed in patients with 2 types of metastatic breast cancer as follows: 1) hormone receptor-positive and human epidermal growth factor receptor 2 negative, and 2) triple-negative disease. Results: This analysis included 925 patients. Patients receiving nab-paclitaxel vs. paclitaxel had significantly longer TTD (median 4.2 vs. 2.8 months, P
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1179-1322
Relation: https://www.dovepress.com/comparative-effectiveness-of-early-line-nab-paclitaxel-vs-paclitaxel-i-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
URL الوصول: https://doaj.org/article/9ef32653c5ae444f91d95b9b26fcce42
رقم الأكسشن: edsdoj.9ef32653c5ae444f91d95b9b26fcce42
قاعدة البيانات: Directory of Open Access Journals
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا